Cleared Special

K262005 - Affera Integrated Mapping System

K262005 is an FDA 510(k) clearance for Affera Integrated Mapping System, manufactured by Medtronic, Inc.. The device is a Class 2 Cardiovascular device with product code DQK cleared through the Special 510(k) pathway after a 67-day FDA review.

K262005 · Medtronic, Inc. · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 2026
Decision
67d
Days
Class 2
Risk

K262005 is an FDA 510(k) clearance for the Affera Integrated Mapping System. Classified as Computer, Diagnostic, Programmable (product code DQK), Class II - Special Controls.

Submitted by Medtronic, Inc. (Mounds View, US). The FDA issued a Cleared decision on August 21, 2026 after a review of 67 days - a notably fast clearance cycle.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.1425 - the FDA cardiovascular device oversight framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: Iterative device modification. Low regulatory complexity profile. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.

View all Medtronic, Inc. devices

FDA 510(k) Submission Details - K262005

510(k) Number K262005 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 15, 2026
Decision Date August 21, 2026
Days to Decision 67 days
Submission Type Special
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
58d faster than avg
Panel avg: 125d · This submission: 67d
Pathway characteristics
Modification to existing cleared device.

DQK Device Classification - Class 2, Special Controls

Product Code DQK Computer, Diagnostic, Programmable
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.1425
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - DQK Computer, Diagnostic, Programmable

All 320
Devices cleared under the same product code (DQK) and FDA review panel - the closest regulatory comparables to K262005.
AVVIGO™+ Multi-Modality Guidance System
K253692 · Boston Scientific · Aug 2026
CorVista System® with PCWP Add-On
K253576 · Analytics For Life, Inc. · Jul 2026
EnSite™ X EP System
K262006 · Abbott Medical · Jul 2026
ScioCardio ECG Analysis Platform
K252978 · Synergen Technology Labs, LLC · Jul 2026
ILR ECG Analyzer (IM007)
K253463 · Implicity, Inc. · Jul 2026
OneStim-DUO Cardiac Stimulator (MP5003-4CO)
K253088 · Micropace Pty, Ltd. · Jun 2026